• Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens
  • A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas
  • AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount
  • Dividend Investing Newsletter and model portfolio that focuses on dividend growth
  • AAII Growth Investing Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.
  • Retirement Investing Discover trusted strategies for every stage of retirement. Get actionable insights and resources for smart retirement planning.
  • Sentiment Investing A research-driven newsletter with 10+ signals decoding sentiment across retail and institutional behavior.
  • Stock Superstars Report Get stock ideas inspired by the market's leading professionals
  • VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio
  • Bits and Bips Newsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Explore All Membership Options
Join Now

Stock Evaluator: Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc. AUPH

$14.88 -0.12 -0.80%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,654,921
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Commentary & Analysis

Financial Summary

Share Statistics AUPH Industry
Median		 Percentile
(All Stocks)
Market Cap (Mil) $1,913.6 $252.6 53%
Shares Out (Mil) 137.6 52.3 69%
Institutional Ownership 98.5% 92.1% 80%
Float (Mil) 126.2 40.2 66%
Beta 1.41 0.95 80%
Avg Daily Volume (000s) 1,068 455 72%
Price Change
(52-week)		 64.4% 52.9% 85%
Growth AUPH Industry
Median		 Percentile
(All Stocks)
Sales (5yr) 41.4% 13.6% 94%
Net Income (5yr) 36.8% (9.9%) 89%
EPS (5yr) 34.4% 16.0% 84
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 41.0% (15.6%) 91%
Estimates Qtrly Current
Fiscal
Year		 Next
Fiscal
Year
# of Estimates 5 5 6
Current EPS $0.240 $0.950 $1.107
Month Ago EPS $0.248 $0.960 $1.118
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS $0.203 $0.813 $0.820
Year/Year Chg (4.0%) (54.1%) (36.8%)
Financials AUPH Industry
Median		 Percentile
(All Stocks)
Sales (TTM) (Mil) $298 $38 36%
Net Income (TTM) (Mil) $298 ($43) 73%
EPS (TTM) $2.247 ($1.600) 74%
Operating Cash Flow (TTM) (Mil) $167 ($31) 57%
Net Cash Flow (TTM) (Mil) ($25) $5 24%
Long-Term Debt (Q1) (Mil) $51 $5 39%
Enterprise Value (Q1) (Mil) $1,698 $180 47%
Valuation AUPH Industry
Median		 Percentile
(All Stocks)
P/B 3.43 2.56 69%
P/E 6.8 19.0 7%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.2 0.9 8%
Ratios AUPH Industry
Median		 Percentile
(All Stocks)
Gross Margin 78.3% 63.8% 88%
Net Margin 100.0% (67.3%) 99%
ROA 48.5% (49.8%) 99%
ROE 65.0% (55.5%) 94%
Liabilities to Assets 21.6% 30.3% 14%
F-Score 7 3 84%

Passing Stock Screens

As of 7/31/2026, from a list of 60 stock screening strategies, AUPH meetings the criteria of 3 screen:
Stock Screen
FACTOR STRATEGY

Fundamental Rule of Thumb Screen

Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market. 
Performance Since Inception: 6.6%
+/- S&P 500: -0.9

Passing Stocks

3 E Network Technology Group Limited MASK
Advanced Biomed Inc. ADVB
AGM Group Holdings Inc. AGMH
Arbutus Biopharma Corporation ABUS
AsiaStrategy SORA
See All 50 Stocks (as of 7/31/2026)
FACTOR STRATEGY

Price-to-Sales Screen

Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios. 
Performance Since Inception: 13.0%
+/- S&P 500: +5.5

Passing Stocks

ACADIA Pharmaceuticals Inc. ACAD
Accel Entertainment, Inc. ACEL
Afya Limited AFYA
Arbutus Biopharma Corporation ABUS
Asbury Automotive Group, Inc. ABG
See All 44 Stocks (as of 7/31/2026)
FACTOR STRATEGY

Return on Equity Screen

Factors: Quality, Growth
A screen that identifies stocks with above average earnings and sales growth that have consistently outperformed their peers measured by ROE. 
Performance Since Inception: 13.1%
+/- S&P 500: +5.6

Passing Stocks

Aurinia Pharmaceuticals Inc. AUPH
Comfort Systems USA, Inc. FIX
DLocal Limited DLO
Electromed, Inc. ELMD
EMCOR Group, Inc. EME
See All 19 Stocks (as of 7/31/2026)

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors